StockData
BridgeBio Oncology Therapeutics, Inc. logo

BridgeBio Oncology Therapeutics, Inc. (BBOT) stock

BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.80−0.14 (-6.96%)

Close on Nov 18, 2026Market cap $144.72MP/E –Yield –

BridgeBio Oncology Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More BridgeBio Oncology Therapeutics figures

See a number that looks wrong?